These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
222 related items for PubMed ID: 9426205
41. The oncogenic versions of the Ret and Trk tyrosine kinases bind Shc and Grb2 adaptor proteins. Borrello MG, Pelicci G, Arighi E, De Filippis L, Greco A, Bongarzone I, Rizzetti M, Pelicci PG, Pierotti MA. Oncogene; 1994 Jun; 9(6):1661-8. PubMed ID: 8183561 [Abstract] [Full Text] [Related]
42. MEN2A-RET-induced cellular transformation by activation of STAT3. Schuringa JJ, Wojtachnio K, Hagens W, Vellenga E, Buys CH, Hofstra R, Kruijer W. Oncogene; 2001 Aug 30; 20(38):5350-8. PubMed ID: 11536047 [Abstract] [Full Text] [Related]
43. Characterization of Ret-Shc-Grb2 complex induced by GDNF, MEN 2A, and MEN 2B mutations. Ohiwa M, Murakami H, Iwashita T, Asai N, Iwata Y, Imai T, Funahashi H, Takagi H, Takahashi M. Biochem Biophys Res Commun; 1997 Aug 28; 237(3):747-51. PubMed ID: 9299438 [Abstract] [Full Text] [Related]
44. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Mulligan LM, Kwok JB, Healey CS, Elsdon MJ, Eng C, Gardner E, Love DR, Mole SE, Moore JK, Papi L. Nature; 1993 Jun 03; 363(6428):458-60. PubMed ID: 8099202 [Abstract] [Full Text] [Related]
45. Abl tyrosine kinase in signal transduction and cell-cycle regulation. Wang JY. Curr Opin Genet Dev; 1993 Feb 03; 3(1):35-43. PubMed ID: 8453272 [Abstract] [Full Text] [Related]
46. Glial cell line-derived neurotrophic factor differentially stimulates ret mutants associated with the multiple endocrine neoplasia type 2 syndromes and Hirschsprung's disease. Carlomagno F, Melillo RM, Visconti R, Salvatore G, De Vita G, Lupoli G, Yu Y, Jing S, Vecchio G, Fusco A, Santoro M. Endocrinology; 1998 Aug 03; 139(8):3613-9. PubMed ID: 9681515 [Abstract] [Full Text] [Related]
47. Possible involvement of VEGF-FLT tyrosine kinase receptor system in normal and tumor angiogenesis. Shibuya M, Seetharam L, Ishii Y, Sawano A, Gotoh N, Matsushime H, Yamaguchi S. Princess Takamatsu Symp; 1994 Aug 03; 24():162-70. PubMed ID: 8983073 [Abstract] [Full Text] [Related]
48. Tissue-specific carcinogenesis in transgenic mice expressing the RET proto-oncogene with a multiple endocrine neoplasia type 2A mutation. Kawai K, Iwashita T, Murakami H, Hiraiwa N, Yoshiki A, Kusakabe M, Ono K, Iida K, Nakayama A, Takahashi M. Cancer Res; 2000 Sep 15; 60(18):5254-60. PubMed ID: 11016655 [Abstract] [Full Text] [Related]
50. Identification and analysis of the ret proto-oncogene promoter region in neuroblastoma cell lines and medullary thyroid carcinomas from MEN2A patients. Itoh F, Ishizaka Y, Tahira T, Yamamoto M, Miya A, Imai K, Yachi A, Takai S, Sugimura T, Nagao M. Oncogene; 1992 Jun 15; 7(6):1201-6. PubMed ID: 1350670 [Abstract] [Full Text] [Related]
51. A unique signal transduction from FLT tyrosine kinase, a receptor for vascular endothelial growth factor VEGF. Seetharam L, Gotoh N, Maru Y, Neufeld G, Yamaguchi S, Shibuya M. Oncogene; 1995 Jan 05; 10(1):135-47. PubMed ID: 7824266 [Abstract] [Full Text] [Related]
52. Regulators of endocytosis maintain localized receptor tyrosine kinase signaling in guided migration. Jékely G, Sung HH, Luque CM, Rørth P. Dev Cell; 2005 Aug 05; 9(2):197-207. PubMed ID: 16054027 [Abstract] [Full Text] [Related]
54. Tight linkage of the ret proto-oncogene with the multiple endocrine neoplasia type 2A locus. Yamamoto M, Miki T, Tanaka N, Miya A, Shin E, Karakawa K, Kobayashi T, Tahira T, Ishizaka Y, Itoh F. Jpn J Clin Oncol; 1991 Jun 05; 21(3):149-52. PubMed ID: 1682518 [Abstract] [Full Text] [Related]
55. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Lyden D, Hattori K, Dias S, Costa C, Blaikie P, Butros L, Chadburn A, Heissig B, Marks W, Witte L, Wu Y, Hicklin D, Zhu Z, Hackett NR, Crystal RG, Moore MA, Hajjar KA, Manova K, Benezra R, Rafii S. Nat Med; 2001 Nov 05; 7(11):1194-201. PubMed ID: 11689883 [Abstract] [Full Text] [Related]
56. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover. Koch A, Scherr M, Breyer B, Mancini A, Kardinal C, Battmer K, Eder M, Tamura T. Oncogene; 2008 Aug 07; 27(34):4678-89. PubMed ID: 18427551 [Abstract] [Full Text] [Related]
57. Cell scattering of SK-N-MC neuroepithelioma cells in response to Ret and FGF receptor tyrosine kinase activation is correlated with sustained ERK2 activation. van Puijenbroek AA, van Weering DH, van den Brink CE, Bos JL, van der Saag PT, de Laat SW, den Hertog J. Oncogene; 1997 Mar 13; 14(10):1147-57. PubMed ID: 9121763 [Abstract] [Full Text] [Related]
58. The RET proto-oncogene in human cancers. Jhiang SM. Oncogene; 2000 Nov 20; 19(49):5590-7. PubMed ID: 11114739 [Abstract] [Full Text] [Related]
59. Biological and biochemical properties of Ret with kinase domain mutations identified in multiple endocrine neoplasia type 2B and familial medullary thyroid carcinoma. Iwashita T, Kato M, Murakami H, Asai N, Ishiguro Y, Ito S, Iwata Y, Kawai K, Asai M, Kurokawa K, Kajita H, Takahashi M. Oncogene; 1999 Jul 01; 18(26):3919-22. PubMed ID: 10445857 [Abstract] [Full Text] [Related]
60. Only the substitution of methionine 918 with a threonine and not with other residues activates RET transforming potential. Cirafici AM, Salvatore G, De Vita G, Carlomagno F, Dathan NA, Visconti R, Melillo RM, Fusco A, Santoro M. Endocrinology; 1997 Apr 01; 138(4):1450-5. PubMed ID: 9075701 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]